🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise worldwide, with estimates suggesting more than 82 million infections annually. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the reality of growing infection rates, the spread of superbugs and the highly restricted available drugs presently on offer.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Secure Authorization

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, also received approval in concurrent days. This medication, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This authorization represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

According to findings detailed in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which uses an injection and a pill. The study included hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors treating patients have expressed hope. Having a single-dose, oral treatment such as this is described as a "revolutionary step" for public health efforts. This is deemed vital to lessen the impact of the infection for individuals and to halt the transmission of untreatable gonorrhoea around the world.